Cardiovascular Outcome Trials of Incretin Therapy (Dipeptidyl Peptidase-4 Inhibitors/Glucagon-Like Peptide-1 Receptor Agonist)
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
In 2008, the United States Food and Drug Administration issued guidance which mandated long-term cardiovascular outcome trials (CVOTs) to assess the safety of new antidiabetic drugs for type 2 diabetes. Since 2008, three CVOTs that have studied dipeptidyl peptidase-4 (DPP-4) inhibitors and four CVOTs of a glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1RA) have been reported. Each of the completed CVOTs showed the noninferiority of respective drugs to placebo for primary CV composite endpoint. Among them, liraglutide and semaglutide showed a reduction of major adverse cardiovascular events. However, the mechanisms for the observed cardiovascular differences between DPP-4 inhibitors and GLP-1RA, and across individual GLP-1RA are not clearly understood. Therefore, this review will summarize the CVOTs of the DPP-4 inhibitors and GLP-1RA, interpretation of cardioprotective results of incretin-based therapy and the possible mechanism of action.
Abstract
In 2008, the United States Food and Drug Administration issued guidance which mandated long-term cardiovascular outcome trials (CVOTs) to assess the safety of new antidiabetic drugs for type 2 diabetes. Since 2008, three CVOTs that have studied dipeptidyl peptidase-4 (DPP-4) inhibitors and four CVOTs of a glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1RA) have been reported. Each of the completed CVOTs showed the noninferiority of respective drugs to placebo for primary CV composite endpoint. Among them, liraglutide and semaglutide showed a reduction of major adverse cardiovascular events. However, the mechanisms for the observed cardiovascular differences between DPP-4 inhibitors and GLP-1RA, and across individual GLP-1RA are not clearly understood. Therefore, this review will summarize the CVOTs of the DPP-4 inhibitors and GLP-1RA, interpretation of cardioprotective results of incretin-based therapy and the possible mechanism of action.
참고문헌 (21)
- UK Prospective Diabetes Study (UKPDS) Group, "Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)", Lancet, 352, pp.837~853 (1998)[DOI]
- American Diabetes Association, "6. Glycemic targets: standards of medical care in diabetes-2018", Diabetes Care, 41, pp.S55~S64 (2018)[DOI]
- Nissen SE, "Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes", N Engl J Med, 356, pp.2457~2471 (2007)[DOI]
- Scirica BM, "Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus", N Engl J Med, 369, pp.1317~1326 (2013)[DOI]
- White WB, "Alogliptin after acute coronary syndrome in patients with type 2 diabetes", N Engl J Med, 369, pp.1327~1335 (2013)[DOI]
- Green JB, "Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes", N Engl J Med, 373, pp.232~242 (2015)[DOI]
- Pfeffer MA, "Lixisenatide in patients with type 2 diabetes and acute coronary syndrome", N Engl J Med, 373, pp.2247~2257 (2015)[DOI]
- Marso SP, "Liraglutide and cardiovascular outcomes in type 2 diabetes", N Engl J Med, 375, pp.311~322 (2016)[DOI]
- Marso SP, "Semaglutide and cardiovascular outcomes in patients with type 2 diabetes", N Engl J Med, 375, pp.1834~1844 (2016)[DOI]
- Holman RR, "Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes", N Engl J Med, 377, pp.1228~1239 (2017)[DOI]
- Drucker DJ, "The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes", Lancet, 368, pp.1696~1705 (2006)[DOI]
- Mannucci E, "Analyses of results from cardiovascular safety trials with DPP-4 inhibitors: cardiovascular outcomes, predefined safety outcomes, and pooled analysis and meta-analysis", Diabetes Care, 39(Suppl 2), pp.S196~S204 (2016)[DOI]
- Scirica BM, "Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial", Circulation, 130, pp.1579~1588 (2014)[DOI]
- Fadini GP, "Cardiovascular effects of DPP-4 inhibition: beyond GLP-1", Vascul Pharmacol, 55, pp.10~16 (2011)[DOI]
- Luconi M, "Perspectives on cardiovascular effects of incretin-based drugs: from bedside to bench, return trip", Int J Cardiol, 241, pp.302~310 (2017)[DOI]
- Xu G, "Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats", Diabetes, 48, pp.2270~2276 (1999)[DOI]
- Kim M, "GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure", Nat Med, 19, pp.567~575 (2013)[DOI]
- Arakawa M, "Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4", Diabetes, 59, pp.1030~1037 (2010)[DOI]
- Cefalu WT, "Cardiovascular outcomes trials in type 2 diabetes: where do we go from here? Reflections from a Diabetes Care Editors' Expert Forum", Diabetes Care, 41, pp.14~31 (2018)[DOI]
- Luconi M, "Perspectives on cardiovascular effects of incretin-based drugs: From bedside to bench, return trip", Int J Cardiol, 241, pp.302~310 (2017)[DOI]
- Bistola V, "Possible mechanisms of direct cardiovascular impact of GLP-1 agonists and DPP4 inhibitors", Heart Fail Rev, 23, pp.377~388 (2018)[DOI]